Resultados de procura - Ramchandren, Radhakrishnan

Advances in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma por Ramchandren, Radhakrishnan

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia por Ramchandren, Radhakrishnan, Schiffer, Charles A

Ligazón do recurso Ligazón do recurso

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma por Johnston, Patrick B., Pinter-Brown, Lauren C., Warsi, Ghulam, White, Kristen, Ramchandren, Radhakrishnan

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study por Goy, Andre, Sinha, Rajni, Williams, Michael E., Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas E.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution por SUKARI, AMMAR, NAGASAKA, MISAKO, ALHASAN, ROBA, PATEL, DHAVAL, WOZNIAK, ANTOINETTE, RAMCHANDREN, RADHAKRISHNAN, VAISHAMPAYAN, ULKA, WEISE, AMY, FLAHERTY, LAWRENCE, JANG, HYEJEONG, KIM, SEONGHO, GADGEEL, SHIRISH

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma por Herrera, Alex F., Goy, Andre, Mehta, Amitkumar, Ramchandren, Radhakrishnan, Pagel, John M., Svoboda, Jakub, Guan, Shanhong, Hill, John S., Kwei, Kevin, Liu, Emily A., Phillips, Tycel

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment por Zhao, Baiteng, Chen, Robert, O'Connor, Owen A., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Matous, Jeffrey V., Fasanmade, Adedigbo A., Manley, Thomas J., Han, Tae H.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL por Goy, Andre, Ramchandren, Radhakrishnan, Ghosh, Nilanjan, Munoz, Javier, Morgan, David S., Dang, Nam H., Knapp, Mark, Delioukina, Maria, Kingsley, Edwin, Ping, Jerry, Beaupre, Darrin M., Neuenburg, Jutta K., Ruan, Jia

Ligazón do recurso Ligazón do recurso Ligazón do recurso

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies por Han, Tae H., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Chen, Robert, Matous, Jeffrey V., Cooper, Maureen, Grove, Laurie E., Alley, Stephen C., Lynch, Carmel M., O’Connor, Owen A.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) p... por Goy, Andre, Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Robertson, Michael J., Avivi, Irit, Rowe, Jacob M., Herbrecht, Raoul, Van Hoof, Achiel, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma por Witzig, Thomas E., Zinzani, Pier Luigi, Habermann, Thomas M., Tuscano, Joseph M., Drach, Johannes, Ramchandren, Radhakrishnan, Besisik, Sevgi Kalayoglu, Takeshita, Kenichi, Bravo, Marie-Laure Casadebaig, Zhang, Lei, Fu, Tommy, Goy, Andre

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation por Gopal, Ajay K., Ramchandren, Radhakrishnan, O'Connor, Owen A., Berryman, Robert B., Advani, Ranjana H., Chen, Robert, Smith, Scott E., Cooper, Maureen, Rothe, Achim, Matous, Jeffrey V., Grove, Laurie E., Zain, Jasmine

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study por Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P., Eliadis, Paul, Peyrade, Frédéric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K., Tam, Constantine S.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies por Bartlett, Nancy L, Chen, Robert, Fanale, Michelle A, Brice, Pauline, Gopal, Ajay, Smith, Scott E, Advani, Ranjana, Matous, Jeffrey V, Ramchandren, Radhakrishnan, Rosenblatt, Joseph D, Huebner, Dirk, Levine, Pamela, Grove, Laurie, Forero-Torres, Andres

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma por Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L., Rosenblatt, Joseph D., Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M., Fenton, Keenan, Huebner, Dirk, Pinelli, Juan M., Kennedy, Dana A., Shustov, Andrei

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma por Dang, Nam H., Ogura, Michinori, Castaigne, Sylvie, Fayad, Luis E., Jerkeman, Mats, Radford, John, Pezzutto, Antonio, Bondarenko, Igor, Stewart, Douglas A., Shnaidman, Michael, Sullivan, Sharon, Vandendries, Erik, Tobinai, Kensei, Ramchandren, Radhakrishnan, Hamlin, Paul A., Giné, Eva, Ando, Kiyoshi

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies por Forero-Torres, Andres, Ramchandren, Radhakrishnan, Yacoub, Abdulraheem, Wertheim, Michael S., Edenfield, William J., Caimi, Paolo, Gutierrez, Martin, Akard, Luke, Escobar, Carolina, Call, Justin, Persky, Daniel, Iyer, Swaminathan, DeMarini, Douglas J., Zhou, Li, Chen, Xuejun, Dawkins, Fitzroy, Phillips, Tycel J.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma por Timmerman, John, Herbaux, Charles, Ribrag, Vincent, Zelenetz, Andrew D., Houot, Roch, Neelapu, Sattva S., Logan, Theodore, Lossos, Izidore S., Urba, Walter, Salles, Gilles, Ramchandren, Radhakrishnan, Jacobson, Caron, Godwin, John, Carpio, Cecilia, Lathers, Deanne, Liu, Yali, Neely, Jaclyn, Suryawanshi, Satyendra, Koguchi, Yoshinobu, Levy, Ronald

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma por Herrera, Alex F., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Ansell, Stephen M., Moskowitz, Craig H., Fenton, Keenan, Ogden, Carol Anne, Taft, David, Zhang, Qu, Kato, Kazunobu, Campbell, Mary, Advani, Ranjana H.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma por Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S. R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, Kuruvilla, John

Ligazón do recurso Ligazón do recurso Ligazón do recurso